- Details
- Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase one study showing promising results with minimal toxicity. The treatment activates dendritic cells, leading to CD8+ T cell recruitment and tumor elimination. Preliminary data indicates a 50% complete...
|
- Details
- Ruchika Talwar and Phil Pierorazio discuss the challenges of burnout and retention within the urology workforce. Dr. Pierorazio underscores the persistence of high burnout rates despite growing awareness and targeted efforts to mitigate them. He discusses the complex demands on urologists, highlighting the broad scope of care that extends beyond surgery to long-term patient management, which often...
|
- Details
- Sam Chang interviews Roger Li about the MoonRISe-1 trial. This phase 3 study explores the use of TAR-210, an innovative intravesical delivery system for the tyrosine kinase inhibitor erdafitinib, targeting patients with intermediate-risk non-muscle-invasive bladder cancer harboring FGFR alterations. Dr. Li explains that TAR-210, administered via a quick in-office procedure, continuously releases e...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|
- Details
- Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...
|
- Details
- Zach Klaassen interviews Ahmed Ghazi about his work in robotic simulation. Dr. Ghazi shares his journey from laparoscopic surgery in Europe to robotic surgery in the US, emphasizing the need for realistic surgical training tools. He developed 3D-printed, hydrogel organs that simulate bleeding, enhancing training realism. At Hopkins, Dr. Ghazi established SLICE (Surgical Learning and Innovation Cen...
|
- Details
- Sam Chang interviews Neal Shore about the KEYNOTE-676 trial. This global study evaluates the efficacy of combining Pembrolizumab with BCG induction and maintenance in patients who had previously received an induction course of BCG without maintenance. Dr. Shore discusses the study’s aim to enhance the effectiveness of BCG therapy in non-muscle invasive bladder cancer (NMIBC) by adding a checkpoint...
|
- Details
- Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....
|
- Details
- Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. He emphasizes the importance of offering bladder-pres...
|
- Details
- Ruchika Talwar interviews Hans Arora about his extensive involvement in organized medicine through the AMA and the AUA. Dr. Arora shares his journey from an MD-PhD student to a key figure in medical advocacy, emphasizing the importance of organized medicine in influencing healthcare policy. He explains how the AMA’s policy-making process through the House of Delegates affects all medical specialti...
|
